Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways

BMC Medical Genomics

Mayte Suárez-Fariñas²  Emma Guttman-Yassky⁷  Thomas Litman³  Suyan Tian⁴  Tianjiao Wang⁴  Christopher T. Workman¹  James G. Krueger⁵  Dana Malajian⁶  David A. Ewald¹ 

[1] Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark;Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA;Molecular Biomedicine, LEO Pharma AS, Ballerup, Denmark;School of Life Science, Jilin University, 2699 Qianjin Street, Changchun 130012, Jilin, China;The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA;Columbia University, College of Physicians and Surgeons, New York, NY, USA;Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

关键词: Expression analysis;    Atherosclerosis;    Transcriptome;    Meta-analysis;    Atopic dermatitis;   

Others  :  1228950
DOI  :  10.1186/s12920-015-0133-x

 received in 2015-03-23, accepted in 2015-09-11,  发布年份 2015

【 摘 要 】

Background

Atopic dermatitis (AD) is a common inflammatory skin disease with limited treatment options. Several microarray experiments have been conducted on lesional/LS and non-lesional/NL AD skin to develop a genomic disease phenotype. Although these experiments have shed light on disease pathology, inter-study comparisons reveal large differences in resulting sets of differentially expressed genes (DEGs), limiting the utility of direct comparisons across studies.

Methods

We carried out a meta-analysis combining 4 published AD datasets to define a robust disease profile, termed meta-analysis derived AD (MADAD) transcriptome.

Results

This transcriptome enriches key AD pathways more than the individual studies, and associates AD with novel pathways, such as atherosclerosis signaling (IL-37, selectin E/SELE). We identified wide lipid abnormalities and, for the first time in vivo, correlated Th2 immune activation with downregulation of key epidermal lipids (FA2H, FAR2, ELOVL3), emphasizing the role of cytokines on the barrier disruption in AD. Key AD “classifier genes” discriminate lesional from nonlesional skin, and may evaluate therapeutic responses.

Conclusions

Our meta-analysis provides novel and powerful insights into AD disease pathology, and reinforces the concept of AD as a systemic disease.

【 授权许可】

   
2015 Ewald et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Boguniewicz M, Leung DYM: Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011, 242(1):233-246.
• [2]Leung DYM: New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int 2013, 62(2):151-161.
• [3]Dhingra N, Suarez-Farinas M, Fuentes-Duculan J, Gittler JK, Shemer A, Raz A, Fischetti VA, Krueger JG, Guttman-Yassky E: Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. J Allergy Clin Immunol 2013, 132(2):498-501.e3.
• [4]Malajian D, & Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73(2):311-318.
• [5]N & Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. Journal of Allergy and Clinical Immunology. 2015;135(2):324-336.
• [6]Olsson M, Broberg A, Jernås M, Carlsson L, Rudemo M, Suurküla M, Svensson P, Benson M: Increased expression of aquaporin 3 in atopic eczema. Allergy 2006, 61(9):1132-1137.
• [7]Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-Duculan J, Cardinale I, Lin P, Bergman R, Bowcock AM, Krueger JG: Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009, 124(6):1235-1244.e58.
• [8]Elias PM, Hatano Y, Williams ML: Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008, 121(6):1337-1343.
• [9]Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, Mitsui H, Cardinale I, de Guzman Strong C, Krueger JG, Guttman-Yassky E, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQF, Mitsui H, Cardinale I, de Guzman Strong C, Krueger JG, Guttman-Yassky E: Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012, 130(6):1344-1354.
• [10]Beck L, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR: Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. N Engl J Med 2014, 371(2):130-139.
• [11]Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, Johnson-Huang L, Chiricozzi A, Cardinale I, Duan S, Bowcock A, Krueger JG, Guttman-Yassky E: Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011, 128(3):583-93.e1–4.
• [12]Khattri S, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, Finney R, & Guttman-Yassky E. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal of Allergy and Clinical Immunology. 2014;133(6):1626-634.
• [13]Jensen JM, Pfeiffer S, Witt M, Bräutigam M, Neumann C, Weichenthal M, Schwarz T, Fölster-Holst R, Proksch E: Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009, 123:1124-1133.
• [14]Plager A, Leontovich AA, Henke SA, Davis MDP, McEvoy MT, Sciallis GF, Pittelkow MR: Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp Dermatol 2007, 16(1):28-36.
• [15]Suárez-Fariñas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I, Duan S, Bowcock AM, Krueger JG, Guttman-Yassky E: Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011, 127(4):954-64.e1–4.
• [16]Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG: Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009, 124(5):1022-10.e1–395.
• [17]Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW: IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012, 130(1):1-18.
• [18]Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E: Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014, 134(6):1293-1300.
• [19]Jiang K, Frank MB, Chen Y, Osban J, Jarvis JN: Genomic characterization of remission in juvenile idiopathic arthritis. Arthritis Res Ther 2013, 15(4):R100.
• [20]Cahan P, Rovegno F, Mooney D, Newman JC, St Laurent G, McCaffrey TA: Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. Gene 2007, 401(1–2):12-18.
• [21]Ramasamy A, Mondry A, Holmes CC, Altman DG: Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med 2008, 5(9):e184.
• [22]Zakharkin SO, Kim K, Mehta T, Chen L, Barnes S, Scheirer KE, Parrish RS, Allison DB, Page GP: Sources of variation in Affymetrix microarray experiments. BMC Bioinformatics 2005, 6:214.
• [23]Suárez-Fariñas M, Noggle S, Heke M, Hemmati-Brivanlou A, Magnasco MO: Comparing independent microarray studies: the case of human embryonic stem cells. BMC Genomics 2005, 6:99.
• [24]Suárez-Fariñas M, Lowes MA, Zaba LC, Krueger JG: Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One 2010, 5(4):e10247.
• [25]Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, Suárez-Fariñas M: Meta-analysis derived (MAD) transcriptome of psoriasis defines the ‘core’ pathogenesis of disease. PLoS One 2012, 7(9):e44274.
• [26]Chang L-C, Lin H-M, Sibille E, Tseng GC: Meta-analysis methods for combining multiple expression profiles: comparisons, statistical characterization and an application guideline. BMC Bioinformatics 2013, 14(vi):368.
• [27]Choi JK, Yu U, Kim S, Yoo OJ: Combining multiple microarray studies and modeling interstudy variation. Bioinformatics 2003, 19(Suppl 1):i84-i90.
• [28]Tseng GC, Ghosh D, Feingold E: Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res 2012, 40(9):3785-3799.
• [29]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6(7):e1000100.
• [30]Team R, Core. "R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2012." (2014).
• [31]Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JYH, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80.
• [32]Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F: A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Stat Assoc 2004, 99(468):909-917.
• [33]Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8(1):118-127.
• [34]Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD: The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012, 28(6):882-883.
• [35]Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE, Geman D, Baggerly K, Irizarry RA: Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010, 11:733-739.
• [36]Parmigiani G: A Cross-Study Comparison of Gene Expression Studies for the Molecular Classification of Lung Cancer. Clin Cancer Res 2004, 10(9):2922-2927.
• [37]Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995, 57(1):289-300.
• [38]Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
• [39]Suárez-Fariñas M, Arbeit R, Jiang W, Ortenzio FS, Sullivan T, Krueger JG: Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. PLoS One 2013, 8(12):e84634.
• [40]Langfelder P, Horvath S: WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008, 9:559.
• [41]Ma S, Huang J: Regularized gene selection in cancer microarray meta-analysis. BMC Bioinformatics 2009, 10:1.
• [42]Tian S, Suarez-Farinas M: Multi-TGDR: a regularization method for multi-class classification in microarray experiments. PLoS One 2013, 8(11):e78302.
• [43]Mitsui H, Suárez-Fariñas M, Belkin DA, Levenkova N, Fuentes-Duculan J, Coats I, Fujita H, Krueger JG: Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol 2012, 132(6):1615-1626.
• [44]Rappaport N, Nativ N, Stelzer G, Twik M, Guan-Golan Y, Stein TI, Bahir I, Belinky F, Morrey CP, Safran M, Lancet D: MalaCards: an integrated compendium for diseases and their annotation. Database (Oxford) 2013, 2013:bat018.
• [45]Appace: Solr. 2014.
• [46]Wittkowski KM, Song T: Nonparametric methods for molecular biology. Methods Mol Biol 2010, 620:105-153.
• [47]Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JGN, Geoghegan J, Germino G, Griffin C, Hilmer SC, Hoffman E, Jedlicka AE, Kawasaki E, Martínez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye SQ, Yu W: Multiple-laboratory comparison of microarray platforms. Nat Methods 2005, 2(5):345-350.
• [48]Lowes MA, Suárez-Fariñas M, Krueger JG: Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-255.
• [49]Panzer R, Blobel C, Fölster-Holst R, Proksch E: TLR2 and TLR4 expression in atopic dermatitis, contact dermatitis and psoriasis. Exp Dermatol 2014, 23(5):364-366.
• [50]Kuo I-H, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC, Gallo RL, Borkowski AW, Yamasaki K, Leung DY, Georas SN, De Benedetto A, Beck LA: Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair. J Invest Dermatol 2013, 133(4):988-998.
• [51]Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997, 96(12):4219-4225.
• [52]Kiechl S, Paré G, Barbalic M, Qi L, Dupuis J, Dehghan A, Bis JC, Laxton RC, Xiao Q, Bonora E, Willeit J, Xu Q, Witteman JCM, Chasman D, Tracy RP, Ballantyne CM, Ridker PM, Benjamin EJ, Ye S: Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: a meta-analysis. Circ Cardiovasc Genet 2011, 4(6):681-686.
• [53]Mead JR, Ramji DP: The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc Res 2002, 55(2):261-269.
• [54]Chen Q, Razzaghi H, Demirci FY, Kamboh MI: Functional significance of lipoprotein lipase HindIII polymorphism associated with the risk of coronary artery disease. Atherosclerosis 2008, 200(1):102-108.
• [55]Goldberg IJ: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37(4):693-707.
• [56]Xu X, Wang L, Xu C, Zhang P, Yong F, Liu H, Wang J, Shi Y: Variations in matrix metalloproteinase-1, −3, and −9 genes and the risk of acute coronary syndrome and coronary artery disease in the Chinese Han population. Coron Artery Dis 2013, 24(4):259-265.
• [57]Abilleira S, Bevan S, Markus HS: The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 2006, 43(12):897-901.
• [58]Averill MM, Kerkhoff C, Bornfeldt KE: S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012, 32(2):223-229.
• [59]Jin S, Park CO, Shin JU, Noh JY, Lee YS, Lee NR, Kim HR, Noh S, Lee Y, Lee J-H, Lee KH: DAMP molecules S100A9 and S100A8 activated by IL-17A and house-dust mites are increased in atopic dermatitis. Exp Dermatol 2014, 23(12):938-941.
• [60]Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, Meng K, Wu B, Yu K, Chai M, Liu Y, Zhou Y: Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediators Inflamm 2014, 2014:165742.
• [61]Inouye M, Ripatti S, Kettunen J, Lyytikäinen L-P, Oksala N, Laurila P-P, Kangas AJ, Soininen P, Savolainen MJ, Viikari J, Kähönen M, Perola M, Salomaa V, Raitakari O, Lehtimäki T, Taskinen M-R, Järvelin M-R, Ala-Korpela M, Palotie A, de Bakker PIW: Novel Loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet 2012, 8(8):e1002907.
• [62]Tregouet DA, Barbaux S, Poirier O, Blankenberg S, Bickel C, Escolano S, Rupprecht HJ, Meyer J, Cambien F, Tiret L: SELPLG gene polymorphisms in relation to plasma SELPLG levels and coronary artery disease. Ann Hum Genet 2003, 67(Pt 6):504-511.
• [63]Esaki H, Ewald DA, Ungar B, Rozenblit M: Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 2015, 135(1):153-163.
• [64]Choi UY, Kang JS, Hwang YS, Kim YJ. Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases. Experimental & molecular medicine. 2015;47(3):e144.
• [65]Wensink AC, Hack CE, Bovenschen N: Granzymes Regulate Proinflammatory Cytokine Responses. J Immunol 2015, 194(2):491-497.
• [66]Westerberg R, Mansson JE, Golozoubova V, Shabalina IG, Backlund EC, Tvrdik P, Retterstol K, Capecchi MR, Jacobsson A: ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue. J Biol Chem 2006, 281(8):4958-4968.
• [67]Turlo K, Leung CS, Seo JJ, Goulbourne CN, Adeyo O, Gin P, Voss C, Bensadoun A, Fong LG, Young SG, Beigneux AP: Equivalent binding of wild-type lipoprotein lipase (LPL) and S447X-LPL to GPIHBP1, the endothelial cell LPL transporter. Biochim Biophys Acta 2014, 1841(7):963-969.
• [68]Goulbourne CN, Gin P, Tatar A, Nobumori C, Hoenger A, Jiang H, Grovenor CRM, Adeyo O, Esko JD, Goldberg IJ, Reue K, Tontonoz P, Bensadoun A, Beigneux AP, Young SG, Fong LG: The GPIHBP1-LPL complex is responsible for the margination of triglyceride-rich lipoproteins in capillaries. Cell Metab 2014, 19(5):849-860.
• [69]Pan Y-S, Lee Y-S, Lee Y-L, Lee W-C, Hsieh S-Y: Differentially profiling the low-expression transcriptomes of human hepatoma using a novel SSH/microarray approach. BMC Genomics 2006, 7:131.
• [70]Tortola L, Rosenwald E, Abel B, Blumberg H, Schäfer M, Coyle AJ, Renauld J-C, Werner S, Kisielow J, Kopf M: Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest 2012, 122(11):3965-3976.
• [71]Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11(11):1014-1022.
• [72]da Rosa JC, Malajian D, Shemer A, Rozenblit M, Dhingra N, Czarnowicki T, et al. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. Journal of Allergy and Clinical Immunology, 2015:135(3):712-20.
• [73]van Smeden J, Janssens M, Kaye ECJ, Caspers PJ, Lavrijsen AP, Vreeken RJ, Bouwstra JA: The importance of free fatty acid chain length for the skin barrier function in atopic eczema patients. Exp Dermatol 2014, 23:45-52.
• [74]Lee Y, Je Y-J, Lee S-S, Li ZJ, Choi D-K, Kwon Y-B, Sohn K-C, Im M, Seo YJ, Lee JH: Changes in transepidermal water loss and skin hydration according to expression of aquaporin-3 in psoriasis. Ann Dermatol 2012, 24(2):168-174.
• [75]Stachowitz S, Alessandrini F, Abeck D, Ring J, Behrendt H: Permeability barrier disruption increases the level of serine palmitoyltransferase in human epidermis. J Invest Dermatol 2002, 119(5):1048-1052.
• [76]Sawada E, Yoshida N, Sugiura A, Imokawa G: Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitis. J Dermatol Sci 2012, 68(1):25-35.
• [77]Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S: Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 2000, 143(3):524-531.
• [78]Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, El Ghalbzouri A, Bouwstra JA: TNF-α and Th2 Cytokines Induce Atopic Dermatitis-Like Features on Epidermal Differentiation Proteins and Stratum Corneum Lipids in Human Skin Equivalents. J Invest Dermatol 2014, 134(7):1941-1950.
• [79]Hirota T, Saeki H, Tomita K, Tanaka S, Ebe K, Sakashita M, Yamada T, Fujieda S, Miyatake A, Doi S, Enomoto T, Hizawa N, Sakamoto T, Masuko H, Sasaki T, Ebihara T, Amagai M, Esaki H, Takeuchi S, Furue M, Noguchi E, Kamatani N, Nakamura Y, Kubo M, Tamari M: Variants of C-C motif chemokine 22 (CCL22) are associated with susceptibility to atopic dermatitis: case–control studies. PLoS One 2011, 6(11):e26987.
• [80]Hussein YM, Shalaby SM, Nassar A, Alzahrani SS, Alharbi AS, Nouh M: Association between genes encoding components of the IL-4/IL-4 receptor pathway and dermatitis in children. Gene 2014, 545(2):276-281.
• [81]Gao P-S, Rafaels NM, Mu D, Hand T, Murray T, Boguniewicz M, Hata T, Schneider L, Hanifin JM, Gallo RL, Gao L, Beaty TH, Beck LA, Leung DYM, Barnes KC: Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol 2010, 125(6):1403-1407.e4.
• [82]Langfelder P, Horvath S: WGCNA package FAQ. 2014. [Online]. Available: http://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/faq.html. [Accessed: 03-Mar-2015]
• [83]Hon KL, Ching GK, Ng PC, Leung TF: Exploring CCL18, eczema severity and atopy. Pediatr Allergy Immunol 2011, 22(7):704-707.
• [84]Niebuhr M, Mamerow D, Heratizadeh A, Satzger I, Werfel T: Staphylococcal alpha-toxin induces a higher T cell proliferation and interleukin-31 in atopic dermatitis. Int Arch Allergy Immunol 2011, 156(4):412-415.
• [85]Guttman-Yassky E, Dhingra N, Leung DYM: New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013, 13(4):549-561.
• [86]Rozenblit M, Suarez-Farinas M, Shemer A, Khattri S, Gilleaudeau P, Sullivan-Whalen M, Zheng X, Xu H, Cardinale I, Krueger JG, Guttman-Yassky E: Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. J Allergy Clin Immunol 2014, 134(4):955-957.
• [87]Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R: Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 2009, 64(11):1588-1596.
• [88]Marinović Kulišić S, Lipozenčić J, Gregorović G, Gregurek G, Lacković G, Jurić-Lekić G: Expression of e-selectin in the skin of patients with atopic dermatitis: morphometric study. Acta Dermatovenerol Croat 2010, 18(3):141-145.
• [89]Tsao C-H, Shiau M-Y, Chuang P-H, Chang Y-H, Hwang J: Interleukin-4 regulates lipid metabolism by inhibiting adipogenesis and promoting lipolysis. J Lipid Res 2014, 55(3):385-397.
• [90]Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW, Lavery GG: 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci U S A 2014, 111(24):E2482-E2491.
• [91]Pérez-Montarelo D, Hudson NJ, Fernández AI, Ramayo-Caldas Y, Dalrymple BP, Reverter A: Porcine tissue-specific regulatory networks derived from meta-analysis of the transcriptome. PLoS One 2012, 7(9):e46159.
• [92]Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and Metabolic Syndrome–scientific evidence and therapeutic implications. Journal of medicine and life. 2014;7(4):468.
• [93]Oliveira Mde F, Rocha Bde O, Duarte GV: Psoriasis: classical and emerging comorbidities. An Bras Dermatol 2015, 90(1):9-20.
• [94]Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H, Zheng X, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015.
• [95]Niwa Y, Sumi H, Akamatsu H: An association between ulcerative colitis and atopic dermatitis, diseases of impaired superficial barriers. J Invest Dermatol 2004, 123(5):999-1000.
• [96]Myrelid P, Dufmats M, Lilja I, Grinn C, Lannerstad O, Sjödahl R: Atopic manifestations are more common in patients with Crohn disease than in the general population. Scand J Gastroenterol 2004, 39(8):731-736.
• [97]Cardwell CR, Shields MD, Carson DJ, Patterson CC: A meta-analysis of the association between childhood type 1 diabetes and atopic disease. Diabetes Care 2003, 26(9):2568-2574.
• [98]Schmitt J, Buske-Kirschbaum A, Roessner V: Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy 2010, 65(12):1506-1524.
• [99]7 th International Congress of Psoriasis: from Gene to Clinic The Queen Elizabeth II Conference Centre, London, U.K. 11th-13th December 2014. Br. J. Dermatol. 2014;171:6, e105–e173.
• [100]Dave J, Ahlman MA, Lockshin BN, Bluemke DA, Mehta NN: Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique. J Am Acad Dermatol 2014, 70(6):1137-1138.
• [101]Rose S, Sheth NH, Baker JF, Ogdie A, Raper A, Saboury B, Werner TJ, Thomas P, Vanvoorhees A, Alavi A, Torigian DA, Gelfand JM, Mehta NN: A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. Am J Cardiovasc Dis 2013, 3(4):273-278.
• [102]Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR: Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000, 20(12):2614-2618.
• [103]Nelson JC, Jiang X-C, Tabas I, Tall A, Shea S: Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006, 163(10):903-912.
• [104]Park T-S, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD: Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004, 110(22):3465-3471.
• [105]Tabas I: Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity? Circulation 2004, 110(22):3400-3401.
• [106]van Smeden J, Janssens M, Gooris GS, Bouwstra JA: The important role of stratum corneum lipids for the cutaneous barrier function. Biochim Biophys Acta 2014, 1841(3):295-313.
• [107]Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, Vreeken RJ, Hankemeier T, Kezic S, Wolterbeek R, Lavrijsen AP, Bouwstra JA: Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res 2012, 53(12):2755-2766.
• [108]Fujita H, Shemer A, Suárez-Fariñas M, Johnson-Huang LM, Tintle S, Cardinale I, Fuentes-Duculan J, Novitskaya I, Carucci JA, Krueger JG, Guttman-Yassky E: Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. J Allergy Clin Immunol 2011, 128(3):574-82.e1–12.
• [109]Sääf AM, Tengvall-Linder M, Chang HY, Adler AS, Wahlgren C-FF, Scheynius A, Nordenskjöld M, Bradley M, Saaf AM, Tengvall-Linder M, Chang HY, Adler AS, Wahlgren C-FF, Scheynius A, Nordenskjold M, Bradley M: Global expression profiling in atopic eczema reveals reciprocal expression of inflammatory and lipid genes. PLoS One 2008, 3(12):e4017.
• [110]Hatano Y, Terashi H, Arakawa S, Katagiri K: Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol 2005, 124(4):786-792.
• [111]Hama H: Fatty acid 2-Hydroxylation in mammalian sphingolipid biology. Biochim Biophys Acta 2010, 1801(4):405-414.
• [112]Pappas A: Epidermal surface lipids. Dermatoendocrinol 2009, 1(2):72-76.
• [113]Westerberg R, Tvrdik P, Unden AB, Mansson JE, Norlen L, Jakobsson A, Holleran WH, Elias PM, Asadi A, Flodby P, Toftgard R, Capecchi MR, Jacobsson A: Role for ELOVL3 and fatty acid chain length in development of hair and skin function. J Biol Chem 2004, 279(7):5621-5629.
• [114]Fehrenschild D, Galli U, Breiden B, Bloch W, Schettina P, Brodesser S, Michels C, Gunschmann C, Sandhoff K, Niessen CM, Niemann C: TCF/Lef1-mediated control of lipid metabolism regulates skin barrier function. J Invest Dermatol 2012, 132(2):337-345.
• [115]Blaydon DC, Lind LK, Plagnol V, Linton KJ, Smith FJ, Wilson NJ, McLean WH, Munro CS, South AP, Leigh IM, O’Toole EA, Lundstrom A, Kelsell DP: Mutations in AQP5, encoding a water-channel protein, cause autosomal-dominant diffuse nonepidermolytic palmoplantar keratoderma. Am J Hum Genet 2013, 93(2):330-335.
• [116]Boury-Jamot M, Daraspe J, Bonte F, Perrier E, Schnebert S, Dumas M, Verbavatz JM: Skin aquaporins: function in hydration, wound healing, and skin epidermis homeostasis. Handb Exp Pharmacol 2009, 190:205-217.
• [117]Nejsum LN, Kwon TH, Jensen UB, Fumagalli O, Frokiaer J, Krane CM, Menon AG, King LS, Agre PC, Nielsen S: Functional requirement of aquaporin-5 in plasma membranes of sweat glands. Proc Natl Acad Sci U S A 2002, 99(1):511-516.
• [118]Breuer K, HAussler S, Kapp A, Werfel T: Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002, 147(1):55-61.
• [119]Higaki S, Morohashi M, Yamagishi T, Hasegawa Y: Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999, 38(4):265-269.
• [120]Park H-Y, Kim C-R, Huh I-S, Jung M-Y, Seo E-Y, Park J-H, Lee D-Y, Yang J-M: Staphylococcus aureus Colonization in Acute and Chronic Skin Lesions of Patients with Atopic Dermatitis. Ann Dermatol 2013, 25(4):410-416.
• [121]Matsui K, Nishikawa A: Peptidoglycan from Staphylococcus aureus induces T(H)2 immune response in mice. J Investig Allergol Clin Immunol 2012, 22(2):80-86.
• [122]Warner JA, McGirt LY, Beck LA: Biomarkers of Th2 polarity are predictive of staphylococcal colonization in subjects with atopic dermatitis. Br J Dermatol 2009, 160(1):183-185.
• [123]Niebuhr M, Scharonow H, Gathmann M, Mamerow D, Werfel T: Staphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis. J Allergy Clin Immunol 2010, 126(6):1176-83.e4.